CHRS Q4 2023 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92M+101.8% YoY

Gross Profit

$7M7.6% margin

Operating Income

-$69M-75.3% margin

Net Income

-$80M-87.0% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+22.7%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$630M

Total Liabilities

$823M

Stockholders' Equity

-$193M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$45M	+101.8%
Gross Profit	$7M	$31M	-77.7%
Operating Income	-$69M	-$51M	-33.8%
Net Income	-$80M	-$59M	-35.3%

Revenue Segments

Product Revenue

$166M100%

Other

$322,0000%